SNCA Recombinant Monoclonal Antibody

Overview

This is a monoclonal anti-SNCA antibody raised in Mouse, with confirmed utility in ELISA, IHC, IF, FC. It is designed to detect SNCA protein in Human and supports researchers working in neuroscience contexts.

Key elements and design rationale

• Immunogen: Recombinant Human SNCA protein — determines the epitope region; confirm compatibility with sample preparation and expected post-translational modifications.
• Host species (Mouse): Requires anti-mouse-IgG secondary reagents for indirect detection.
• Monoclonal format: Single-epitope binding provides high specificity and lot-to-lot reproducibility. Confirm epitope accessibility under your assay conditions.
• Isotype (IgG2a): Matched secondary antibodies and isotype controls required. Compatible with standard Protein A/G purification workflows.
• Purification (Affinity chromatography): Enriches for specific immunoglobulin classes; reduces non-specific background vs. crude antisera.

Biological background

SNCA (also referred to as Alpha synuclein, Alpha-synuclein, Alpha-synuclein, isoform NACP140, alphaSYN, MGC105443, MGC110988, MGC127560, MGC64356, NACP, Non A beta component of AD amyloid, Non A4 component of amyloid, Non A4 component of amyloid precursor, Non-A beta component of AD amyloid, Non-A-beta component of alzheimers disease amyloid , precursor of, Non-A4 component of amyloid precursor, Non-A4 component of amyloid, precursor of, OTTHUMP00000218549, OTTHUMP00000218551, OTTHUMP00000218552, OTTHUMP00000218553, OTTHUMP00000218554, PARK 1, PARK 4, PARK1, PARK4, Parkinson disease (autosomal dominant, Lewy body) 4, Parkinson disease familial 1, SNCA, Snca synuclein, Snca synuclein, alpha (non A4 component of amyloid precursor), SYN, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), SYUA_HUMAN) is a protein target studied in Human systems. Expression, subcellular localization, and post-translational modifications vary across cell types and disease states — factors critical to antibody-based detection design. Consult UniProt, NCBI Gene, and primary literature for current annotation of SNCA biology in neuroscience.

Common research applications

• ELISA: Quantification of soluble target in biological fluids or culture supernatants. Ensure samples are within the linear detection range.
• IHC: Visualization of target in FFPE or frozen tissue sections. Optimize antigen retrieval and secondary detection for each tissue type.
• IF: Subcellular localization in fixed cells or tissue sections; fixation and permeabilization conditions affect epitope accessibility.
• FC: Applicable for FC-based detection; refer to product documentation for optimized conditions.

Notes for experimental interpretation

• Isotype controls: Use an isotype-matched (IgG2a from Mouse) control at equivalent concentration to assess non-specific background.
• Cross-reactivity: Confirm the clone does not cross-react with related family members under your assay conditions.
• Matrix effects: Sample matrix can affect performance; pilot dilution linearity and spike-recovery experiments are advised for quantitative studies.
• Species reactivity: Confirmed for Human. Extrapolation to untested species requires empirical validation.

This product is a recombinant monoclonal antibody expressed in HEK293F cells.

• Datasheet (12935085)

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.